CSIMarket



Worst Performing Stocks In Biotechnology & Pharmaceuticals Industry During The Previous 90 Days



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares declined by -6.86% on average, in Biotechnology & Pharmaceuticals Industry during the previous 90 days.

Here are the Worst performing stocks in Biotechnology & Pharmaceuticals Industry.




TCON

$1.26

$-4.5400 -78.28%
Last 90 Days


TCON

$1.26

$-4.5400 -78.28%



Tracon Pharmaceuticals Inc

Tracon Pharmaceuticals Inc shares went down -78.28% during the previous 90 days.


Tracon Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing targeted therapies for cancer and ocular diseases. They primarily collaborate with strategic partners to advance their drug candidates through clinical trials and potentially secure regulatory approval.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 46.439 mill. $ - mill. $ -11.024 mill. 37 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 46.439 mill.


$ - mill.


$ -11.024 mill.

Employees Shares Outstanding P/E

-


37 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CRBU

$1.79

$-5.4300 -75.21%
Last 90 Days


CRBU

$1.79

$-5.4300 -75.21%



Caribou Biosciences Inc

Caribou Biosciences Inc stock went down -75.21% during the previous 90 days.


Caribou Biosciences Inc is a biotechnology company that focuses on the development of gene editing technologies. Their business model involves licensing their proprietary CRISPR-Cas9 platform and collaborating with partners to advance research and therapeutic applications in various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 159.852 mill. $ 33.404 mill. $ -115.260 mill. 89 mill. - Y/Y -30.64 %
Market Cap. Revenues TTM Net Income TTM

$ 159.852 mill.


$ 33.404 mill.


$ -115.260 mill.

Employees Shares Outstanding P/E

-


89 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -30.64 %


MRQ Y/Y - %



GRTS

$0.782

$-1.6280 -67.55%
Last 90 Days


GRTS

$0.782

$-1.6280 -67.55%



Gritstone Bio Inc

Gritstone Bio Inc shares dropped -67.55% during the previous 90 days.


Gritstone Bio Inc is a biotechnology company that focuses on developing personalized cancer immunotherapies. Their business model revolves around utilizing their proprietary genomics platform to identify patient-specific tumor targets and developing therapies that stimulate the immune system to recognize and attack cancer cells.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 90.198 mill. $ 10.225 mill. $ -70.998 mill. 115 mill. - Y/Y -48.20 %
Market Cap. Revenues TTM Net Income TTM

$ 90.198 mill.


$ 10.225 mill.


$ -70.998 mill.

Employees Shares Outstanding P/E

-


115 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -48.20 %


MRQ Y/Y - %



CLDI

$0.204

$-0.4090 -66.72%
Last 90 Days


CLDI

$0.204

$-0.4090 -66.72%



Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc shares dropped -66.72% during the previous 90 days.


Calidi Biotherapeutics Inc*s business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.253 mill. $ - mill. $ -34.216 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 7.253 mill.


$ - mill.


$ -34.216 mill.

Employees Shares Outstanding P/E

-


36 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DNA

$0.4497

$-0.7703 -63.14%
Last 90 Days


DNA

$0.4497

$-0.7703 -63.14%



Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings Inc shares went down -63.14% during the previous 90 days.


Ginkgo Bioworks Holdings Inc is a biotechnology company that focuses on using genetic engineering to develop new organisms for various industries. Their business model includes partnering with companies to create custom-designed organisms for applications such as fragrance production, food and beverage, agriculture, and pharmaceuticals. They generate revenue through collaborations, licensing agreements, and providing access to their platform for organism design and development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 901.800 mill. $ 254.644 mill. $ -847.086 mill. 2,005 mill. - Y/Y -61.39 %
Market Cap. Revenues TTM Net Income TTM

$ 901.800 mill.


$ 254.644 mill.


$ -847.086 mill.

Employees Shares Outstanding P/E

-


2,005 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -61.39 %


MRQ Y/Y - %



TRML

$16.96

$-24.8000 -59.39%
Last 90 Days


TRML

$16.96

$-24.8000 -59.39%



Tourmaline Bio Inc

Tourmaline Bio Inc stock declined -59.39% during the previous 90 days.


Tourmaline Bio Inc*s business model revolves around the development and commercialization of innovative healthcare solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 408.431 mill. $ - mill. $ -32.938 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 408.431 mill.


$ - mill.


$ -32.938 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CCCC

$4.38

$-6.2500 -58.80%
Last 90 Days


CCCC

$4.38

$-6.2500 -58.80%



C4 Therapeutics Inc

C4 Therapeutics Inc shares dropped -58.80% during the previous 90 days.


C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid? platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body*s natural protein degradation machinery.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 299.733 mill. $ 20.036 mill. $ -126.074 mill. 68 mill. - Y/Y -19.15 %
Market Cap. Revenues TTM Net Income TTM

$ 299.733 mill.


$ 20.036 mill.


$ -126.074 mill.

Employees Shares Outstanding P/E

-


68 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -19.15 %


MRQ Y/Y - %



FNCH

$1.44

$-1.9783 -57.87%
Last 90 Days


FNCH

$1.44

$-1.9783 -57.87%



Finch Therapeutics Group Inc

Finch Therapeutics Group Inc stock went down -57.87% during the previous 90 days.


Finch Therapeutics Group Inc*s business model revolves around developing microbiome-based therapies for various diseases and conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.311 mill. $ - mill. $ -100.313 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.311 mill.


$ - mill.


$ -100.313 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IVVD

$1.58

$-2.1400 -57.53%
Last 90 Days


IVVD

$1.58

$-2.1400 -57.53%



Invivyd Inc

Invivyd Inc stock dropped -57.53% during the previous 90 days.


Invivyd Inc is a company that operates on a particular business model to deliver its products or services, but without providing any further details.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 173.413 mill. $ - mill. $ -169.563 mill. 110 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 173.413 mill.


$ - mill.


$ -169.563 mill.

Employees Shares Outstanding P/E

-


110 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ADVM

$7.62

$-10.2800 -57.43%
Last 90 Days


ADVM

$7.62

$-10.2800 -57.43%



Adverum Biotechnologies Inc

Adverum Biotechnologies Inc stock declined -57.43% during the previous 90 days.


Adverum Biotechnologies Inc*s business model is focused on developing gene therapies using its proprietary platform to deliver therapeutics for eye diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 125.570 mill. $ - mill. $ -112.896 mill. 16 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 125.570 mill.


$ - mill.


$ -112.896 mill.

Employees Shares Outstanding P/E

-


16 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



WINT

$3.1

$-4.1720 -57.37%
Last 90 Days


WINT

$3.1

$-4.1720 -57.37%



Windtree Therapeutics Inc

Windtree Therapeutics Inc shares went down -57.37% during the previous 90 days.


Windtree Therapeutics Inc is a biotechnology company that develops novel gene therapies to treat respiratory diseases by delivering therapeutic proteins to the lungs. They aim to address unmet medical needs and improve the lives of patients through their innovative treatment approaches.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.080 mill. $ - mill. $ -5.961 mill. 0 mill. 0.01 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.080 mill.


$ - mill.


$ -5.961 mill.

Employees Shares Outstanding P/E

-


0 mill.


0.01

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



INBX

$15.7

$-19.4600 -55.35%
Last 90 Days


INBX

$15.7

$-19.4600 -55.35%



Inhibrx Inc

Inhibrx Inc stock went down -55.35% during the previous 90 days.


Inhibrx Inc operates using a business model that focuses on the development and commercialization of therapeutics. The company leverages its innovative technology platform to create a diverse pipeline of biologics for the treatment of various diseases. Inhibrx Inc aims to collaborate with strategic partners to advance the development of its pipeline and expand its reach in the healthcare market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 856.498 mill. $ - mill. $ -271.155 mill. 55 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 856.498 mill.


$ - mill.


$ -271.155 mill.

Employees Shares Outstanding P/E

-


55 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



FATE

$3.61

$-4.2800 -54.25%
Last 90 Days


FATE

$3.61

$-4.2800 -54.25%



Fate Therapeutics Inc

Fate Therapeutics Inc shares went down -54.25% during the previous 90 days.


Fate Therapeutics Inc*s business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 355.831 mill. $ 106.213 mill. $ -173.169 mill. 99 mill. - Y/Y -87.02 %
Market Cap. Revenues TTM Net Income TTM

$ 355.831 mill.


$ 106.213 mill.


$ -173.169 mill.

Employees Shares Outstanding P/E

208


99 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -87.02 %


MRQ Y/Y - %



ALLO

$2.35

$-2.7300 -53.74%
Last 90 Days


ALLO

$2.35

$-2.7300 -53.74%



Allogene Therapeutics Inc

Allogene Therapeutics Inc stock went down -53.74% during the previous 90 days.


Allogene Therapeutics Inc has a business model that focuses on developing and commercializing innovative allogeneic CAR T cell therapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 397.452 mill. $ 0.065 mill. $ -293.561 mill. 169 mill. - Y/Y -57.69 %
Market Cap. Revenues TTM Net Income TTM

$ 397.452 mill.


$ 0.065 mill.


$ -293.561 mill.

Employees Shares Outstanding P/E

-


169 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -57.69 %


MRQ Y/Y - %



KOD

$2.81

$-3.0900 -52.37%
Last 90 Days


KOD

$2.81

$-3.0900 -52.37%



Kodiak Sciences Inc

Kodiak Sciences Inc shares dropped -52.37% during the previous 90 days.


Kodiak Sciences Inc operates as a biopharmaceutical company that focuses on researching, developing, and commercializing innovative therapeutics to treat various retinal diseases. Their business model revolves around the discovery and development of novel drugs, while also conducting clinical trials and pursuing partnerships to bring these therapies to the market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 147.400 mill. $ - mill. $ -271.423 mill. 52 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 147.400 mill.


$ - mill.


$ -271.423 mill.

Employees Shares Outstanding P/E

-


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VXRT

$0.5724

$-0.5776 -50.23%
Last 90 Days


VXRT

$0.5724

$-0.5776 -50.23%



Vaxart Inc

Vaxart Inc shares went down -50.23% during the previous 90 days.


Vaxart Inc*s business model involves the development of oral vaccines through their proprietary tablet vaccine delivery platform.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 96.627 mill. $ 8.885 mill. $ -81.742 mill. 169 mill. - Y/Y 223.11 %
Market Cap. Revenues TTM Net Income TTM

$ 96.627 mill.


$ 8.885 mill.


$ -81.742 mill.

Employees Shares Outstanding P/E

-


169 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 223.11 %


MRQ Y/Y - %



OMGA

$2.03

$-2.0200 -49.88%
Last 90 Days


OMGA

$2.03

$-2.0200 -49.88%



Omega Therapeutics Inc

Omega Therapeutics Inc stock dropped -49.88% during the previous 90 days.


Omega Therapeutics Inc is a biotechnology company that focuses on developing therapies by leveraging the power of epigenetics. Their business model involves utilizing their proprietary Omega Epigenomic Programming technology to target specific genes and modulate their activity, addressing complex diseases at their source. By creating innovative and precise therapeutic interventions, Omega Therapeutics aims to make significant advancements in healthcare.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 111.934 mill. $ 2.840 mill. $ -108.040 mill. 55 mill. - Y/Y 39.66 %
Market Cap. Revenues TTM Net Income TTM

$ 111.934 mill.


$ 2.840 mill.


$ -108.040 mill.

Employees Shares Outstanding P/E

-


55 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 39.66 %


MRQ Y/Y - %



CABA

$10.66

$-9.7200 -47.69%
Last 90 Days


CABA

$10.66

$-9.7200 -47.69%



Cabaletta Bio Inc

Cabaletta Bio Inc shares went down -47.69% during the previous 90 days.


Cabaletta Bio Inc*s business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 473.880 mill. $ - mill. $ -62.481 mill. 44 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 473.880 mill.


$ - mill.


$ -62.481 mill.

Employees Shares Outstanding P/E

-


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NKGN

$1.35

$-1.2100 -47.27%
Last 90 Days


NKGN

$1.35

$-1.2100 -47.27%



Nkgen Biotech Inc

Nkgen Biotech Inc stock went down -47.27% during the previous 90 days.


Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 29.613 mill. $ -10.087 mill. $ -88.715 mill. 22 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 29.613 mill.


$ -10.087 mill.


$ -88.715 mill.

Employees Shares Outstanding P/E

-


22 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BCDA

$3.41

$-2.9125 -46.07%
Last 90 Days


BCDA

$3.41

$-2.9125 -46.07%



Biocardia Inc

Biocardia Inc shares went down -46.07% during the previous 90 days.


Biocardia Inc*s business model involves developing and commercializing innovative medical therapies and devices to treat cardiovascular diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 85.704 mill. $ 0.468 mill. $ -10.337 mill. 25 mill. - Y/Y -14.06 %
Market Cap. Revenues TTM Net Income TTM

$ 85.704 mill.


$ 0.468 mill.


$ -10.337 mill.

Employees Shares Outstanding P/E

-


25 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -14.06 %


MRQ Y/Y - %



IOVA

$8.16

$-6.9400 -45.96%
Last 90 Days


IOVA

$8.16

$-6.9400 -45.96%



Iovance Biotherapeutics inc

Iovance Biotherapeutics Inc stock declined -45.96% during the previous 90 days.


Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient*s own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,172.355 mill. $ 1.904 mill. $ -449.643 mill. 266 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,172.355 mill.


$ 1.904 mill.


$ -449.643 mill.

Employees Shares Outstanding P/E

-


266 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NMRA

$9.78

$-8.2700 -45.82%
Last 90 Days


NMRA

$9.78

$-8.2700 -45.82%



Neumora Therapeutics Inc

Neumora Therapeutics Inc shares declined -45.82% during the previous 90 days.


Neumora Therapeutics Inc*s business model focuses on developing and commercializing novel therapeutic solutions in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 456.638 mill. $ - mill. $ -389.694 mill. 47 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 456.638 mill.


$ - mill.


$ -389.694 mill.

Employees Shares Outstanding P/E

-


47 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RGNX

$12.41

$-10.4400 -45.69%
Last 90 Days


RGNX

$12.41

$-10.4400 -45.69%



Regenxbio Inc

Regenxbio Inc stock declined -45.69% during the previous 90 days.


Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 544.526 mill. $ 99.374 mill. $ -260.540 mill. 44 mill. - Y/Y 9.06 %
Market Cap. Revenues TTM Net Income TTM

$ 544.526 mill.


$ 99.374 mill.


$ -260.540 mill.

Employees Shares Outstanding P/E

300


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 9.06 %


MRQ Y/Y - %



VOR

$1.15

$-0.9500 -45.24%
Last 90 Days


VOR

$1.15

$-0.9500 -45.24%



Vor Biopharma Inc

Vor Biopharma Inc stock dropped -45.24% during the previous 90 days.


Vor Biopharma Inc*s business model focuses on developing novel cell therapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 77.749 mill. $ - mill. $ -115.512 mill. 68 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 77.749 mill.


$ - mill.


$ -115.512 mill.

Employees Shares Outstanding P/E

-


68 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CMPX

$1.11

$-0.8900 -44.50%
Last 90 Days


CMPX

$1.11

$-0.8900 -44.50%



Compass Therapeutics Inc

Compass Therapeutics Inc stock went down -44.50% during the previous 90 days.


Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 151.635 mill. $ - mill. $ -45.444 mill. 137 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 151.635 mill.


$ - mill.


$ -45.444 mill.

Employees Shares Outstanding P/E

-


137 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BCAB

$1.59

$-1.2600 -44.21%
Last 90 Days


BCAB

$1.59

$-1.2600 -44.21%



Bioatla Inc

Bioatla Inc shares dropped -44.21% during the previous 90 days.


Bioatla Inc*s business model focuses on developing and commercializing innovative antibody-based therapeutics to treat various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 76.056 mill. $ - mill. $ -124.080 mill. 48 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 76.056 mill.


$ - mill.


$ -124.080 mill.

Employees Shares Outstanding P/E

-


48 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CRGX

$16.72

$-13.1000 -43.93%
Last 90 Days


CRGX

$16.72

$-13.1000 -43.93%



Cargo Therapeutics Inc

Cargo Therapeutics Inc stock declined -43.93% during the previous 90 days.


Cargo Therapeutics Inc is a biotechnology company that utilizes a unique business model focused on developing targeted therapeutics. Their approach involves engineering cell-penetrating peptides to deliver various cargoes, such as gene therapies or small molecules, directly to specific cells or tissues, increasing precision and effectiveness of treatments. By leveraging this technology, the company aims to address unmet medical needs with potentially transformative therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12.521 mill. $ - mill. $ -126.226 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 12.521 mill.


$ - mill.


$ -126.226 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EDIT

$5.06

$-3.9400 -43.78%
Last 90 Days


EDIT

$5.06

$-3.9400 -43.78%



Editas Medicine Inc

Editas Medicine Inc stock dropped -43.78% during the previous 90 days.


Editas Medicine Inc.*s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 414.611 mill. $ 69.407 mill. $ -166.133 mill. 82 mill. - Y/Y -88.48 %
Market Cap. Revenues TTM Net Income TTM

$ 414.611 mill.


$ 69.407 mill.


$ -166.133 mill.

Employees Shares Outstanding P/E

-


82 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -88.48 %


MRQ Y/Y - %



APTO

$0.89

$-0.6900 -43.67%
Last 90 Days


APTO

$0.89

$-0.6900 -43.67%



Aptose Biosciences Inc

Aptose Biosciences Inc shares went down -43.67% during the previous 90 days.


Aptose Biosciences Inc has a business model focused on developing and commercializing targeted therapies for the treatment of various types of cancers. This involves conducting research, preclinical and clinical development activities, and eventually partnering or licensing their drug candidates to pharmaceutical companies for further development and commercialization.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.781 mill. $ - mill. $ -49.252 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5.781 mill.


$ - mill.


$ -49.252 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SGMO

$0.5001

$-0.3823 -43.33%
Last 90 Days


SGMO

$0.5001

$-0.3823 -43.33%



Sangamo Therapeutics Inc

Sangamo Therapeutics Inc stock went down -43.33% during the previous 90 days.


Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients* lives.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 90.189 mill. $ 18.756 mill. $ -328.053 mill. 180 mill. - Y/Y -99.70 %
Market Cap. Revenues TTM Net Income TTM

$ 90.189 mill.


$ 18.756 mill.


$ -328.053 mill.

Employees Shares Outstanding P/E

411


180 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -99.70 %


MRQ Y/Y - %



ALGS

$0.5

$-0.3800 -43.18%
Last 90 Days


ALGS

$0.5

$-0.3800 -43.18%



Aligos Therapeutics Inc

Aligos Therapeutics Inc shares declined -43.18% during the previous 90 days.


Aligos Therapeutics Inc*s business model involves developing innovative therapeutics for the treatment of viral diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.748 mill. $ 16.385 mill. $ -81.673 mill. 44 mill. - Y/Y -21.12 %
Market Cap. Revenues TTM Net Income TTM

$ 21.748 mill.


$ 16.385 mill.


$ -81.673 mill.

Employees Shares Outstanding P/E

-


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -21.12 %


MRQ Y/Y - %



SABS

$3.15

$-2.3400 -42.62%
Last 90 Days


SABS

$3.15

$-2.3400 -42.62%



Sab Biotherapeutics Inc

Sab Biotherapeutics Inc shares dropped -42.62% during the previous 90 days.


Sab Biotherapeutics Inc*s business model focuses on developing and producing innovative antibody therapeutics using advanced genetic engineering techniques.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16.508 mill. $ 4.095 mill. $ -27.212 mill. 5 mill. - Y/Y -64.69 %
Market Cap. Revenues TTM Net Income TTM

$ 16.508 mill.


$ 4.095 mill.


$ -27.212 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -64.69 %


MRQ Y/Y - %



IKT

$1.41

$-1.0200 -41.98%
Last 90 Days


IKT

$1.41

$-1.0200 -41.98%



Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc shares went down -41.98% during the previous 90 days.


Inhibikase Therapeutics Inc*s business model focuses on using innovative approaches and technologies to develop and commercialize potential therapeutic treatments for serious neurodegenerative diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.533 mill. $ 0.324 mill. $ -19.130 mill. 5 mill. - Y/Y 991.33 %
Market Cap. Revenues TTM Net Income TTM

$ 7.533 mill.


$ 0.324 mill.


$ -19.130 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 991.33 %


MRQ Y/Y - %



SRRK

$9.45

$-6.8300 -41.95%
Last 90 Days


SRRK

$9.45

$-6.8300 -41.95%



Scholar Rock Holding Corp

Scholar Rock Holding Corp stock went down -41.95% during the previous 90 days.


Scholar Rock Holding Corp operates using a business model focused on the development of innovative therapies for the treatment of diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 906.185 mill. $ - mill. $ -183.263 mill. 96 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 906.185 mill.


$ - mill.


$ -183.263 mill.

Employees Shares Outstanding P/E

-


96 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CVM

$1.3

$-0.9100 -41.18%
Last 90 Days


CVM

$1.3

$-0.9100 -41.18%



Cel sci Corporation

Cel Sci Corporation stock went down -41.18% during the previous 90 days.


Cel-Sci Corporation*s business model revolves around developing and commercializing immunotherapy drugs for the treatment of infectious diseases and certain types of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 67.608 mill. $ - mill. $ -29.952 mill. 52 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 67.608 mill.


$ - mill.


$ -29.952 mill.

Employees Shares Outstanding P/E

-


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IPSC

$3.13

$-2.0300 -39.34%
Last 90 Days


IPSC

$3.13

$-2.0300 -39.34%



Century Therapeutics inc

Century Therapeutics Inc stock declined -39.34% during the previous 90 days.


Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 194.988 mill. $ 1.370 mill. $ -133.471 mill. 62 mill. - Y/Y -50.29 %
Market Cap. Revenues TTM Net Income TTM

$ 194.988 mill.


$ 1.370 mill.


$ -133.471 mill.

Employees Shares Outstanding P/E

-


62 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -50.29 %


MRQ Y/Y - %



TCBP

$1.04

$-0.6700 -39.18%
Last 90 Days


TCBP

$1.04

$-0.6700 -39.18%



Tc Biopharm holdings Plc

Tc Biopharm Holdings Plc shares declined -39.18% during the previous 90 days.


Tc Biopharm Holdings Plc*s business model revolves around the development and commercialization of innovative cell therapies for the treatment of various diseases and medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 31.344 mill. $ - mill. $ -10.619 mill. 30 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 31.344 mill.


$ - mill.


$ -10.619 mill.

Employees Shares Outstanding P/E

-


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



TNYA

$3.36

$-2.1600 -39.13%
Last 90 Days


TNYA

$3.36

$-2.1600 -39.13%



Tenaya Therapeutics Inc

Tenaya Therapeutics Inc stock declined -39.13% during the previous 90 days.


Tenaya Therapeutics Inc*s business model is centered around developing novel treatments for heart disease using regenerative medicine approaches, focusing on advanced therapies that repair and restore the heart*s function. They aim to bring these innovative therapies to patients by leveraging their expertise in drug discovery and development, and by collaborating with strategic partners in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 248.388 mill. $ - mill. $ -127.665 mill. 74 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 248.388 mill.


$ - mill.


$ -127.665 mill.

Employees Shares Outstanding P/E

-


74 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GLUE

$3.83

$-2.3900 -38.42%
Last 90 Days


GLUE

$3.83

$-2.3900 -38.42%



Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc shares declined -38.42% during the previous 90 days.


Monte Rosa Therapeutics Inc operates under a specific business model that focuses on a unique approach in the field of therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 190.791 mill. $ - mill. $ -132.882 mill. 50 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 190.791 mill.


$ - mill.


$ -132.882 mill.

Employees Shares Outstanding P/E

-


50 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ABOS

$2.64

$-1.6400 -38.32%
Last 90 Days


ABOS

$2.64

$-1.6400 -38.32%



Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc stock declined -38.32% during the previous 90 days.


Acumen Pharmaceuticals Inc*s business model focuses on developing innovative treatments and therapies for neurodegenerative diseases. They aim to address unmet medical needs through advanced research and cutting-edge technologies, with the goal of improving patients* lives and providing better healthcare solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 157.904 mill. $ 14.796 mill. $ -55.937 mill. 60 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 157.904 mill.


$ 14.796 mill.


$ -55.937 mill.

Employees Shares Outstanding P/E

-


60 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com